ArticleFrontiers in immunology2025
Differential expression profiles of lncRNAs and a preliminary study on the mechanism of lncRNA FAM225A in triple seronegative myasthenia gravis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case report of sequential efgartigimod and rituximab treatment for tSNMG.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-seronegative (Triple-SN) myasthenia gravis (MG) is a subtype of MG, and its diagnosis and treatment are challenging. Our study aims to discover new biomarkers and potential therapeutic targets and explore the preliminary mechanisms of triple-SN MG. Methods: Peripheral blood mononuclear cells (PBMCs) were collected from 15 patients with triple-SN MG who were newly diagnosed with the disease and 15 healthy controls. Various experimental techniques and analysis methods, such as PBMC isolation, microarray analysis, dual-luciferase reporter assay, quantitative real-time polymerase chain reaction (qRT-PCR), cell culture, and transfection, were used. Results: Our study identified 385 differentially expressed genes (DEmRNAs) and 361 differentially expressed lncRNAs (DElncRNAs) in triple-SN MG. Notably, lncRNA FAM225A, one of the top five downregulated DElncRNAs, was verified to decreased and negatively correlated with the clinical severity of triple-SN MG. Functional enrichment analysis, immune infiltration analysis and further experiments revealed that FAM225A affected the imbalance of Th1/Th2 by targeting hsa-miR-150-5p in the pathogenesis of triple-SN MG. Conclusions: This study is the first to provide important clues for understanding the pathological mechanism of triple-SN MG, which might contribute to the discovery of novel diagnostic and therapeutic monitoring biomarkers and new targets for the treatment of triple-SN MG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.